back to top
HomeTagsSignificantly

Significantly

CARVYKTI ® is the First and Solely Cell Remedy to Considerably Lengthen Total Survival In comparison with Normal of Care in Sufferers with A...

Landmark CARTITUDE-4 research outcomes present CARVYKTI ® lowered the danger of dying by 45 % after three-year follow-upLate-breaking information featured in an oral presentation...

New Medical Information Demonstrates Three Years of Steady Therapy with Twin-Appearing LEQEMBI (lecanemab-irmb) Continues to Considerably Profit Early Alzheimer's Illness Sufferers Offered at AAI...

TOKYO and CAMBRIDGE, Mass., Jul 31, 2024 - (JCN Newswire) - - Eisai Co (OTC:)., Ltd. and Biogen Inc (NASDAQ:). introduced at this time...

Most Popular

spot_img